Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1987 1
1988 2
1989 1
1990 2
1991 3
1992 11
1993 28
1994 63
1995 99
1996 124
1997 148
1998 155
1999 183
2000 211
2001 248
2002 234
2003 222
2004 245
2005 292
2006 292
2007 306
2008 320
2009 356
2010 343
2011 358
2012 439
2013 484
2014 540
2015 711
2016 803
2017 942
2018 1034
2019 1081
2020 825
Text availability
Article attribute
Article type
Publication date

Search Results

10,190 results
Results by year
Filters applied: . Clear all
Page 1
CTLA-4: a moving target in immunotherapy.
Rowshanravan B, Halliday N, Sansom DM. Rowshanravan B, et al. Blood. 2018 Jan 4;131(1):58-67. doi: 10.1182/blood-2017-06-741033. Epub 2017 Nov 8. Blood. 2018. PMID: 29118008 Free PMC article. Review.
CD28 and CTLA-4 are members of a family of immunoglobulin-related receptors that are responsible for various aspects of T-cell immune regulation. The family includes CD28, CTLA-4, and ICOS as well as other proteins, including PD-1, BTLA, and TIG …
CD28 and CTLA-4 are members of a family of immunoglobulin-related receptors that are responsible for various aspects of T
CTLA-4 and PD-1 Pathways: Similarities, Differences, and Implications of Their Inhibition.
Buchbinder EI, Desai A. Buchbinder EI, et al. Am J Clin Oncol. 2016 Feb;39(1):98-106. doi: 10.1097/COC.0000000000000239. Am J Clin Oncol. 2016. PMID: 26558876 Free PMC article. Review.
The cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) and programmed death 1 (PD-1) immune checkpoints are negative regulators of T-cell immune function. ...The roles of CTLA-4 and PD-1 in inhibiting immune …
The cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) and programmed death 1 (PD-1) immu …
Immune-related adverse events with immune checkpoint blockade: a comprehensive review.
Michot JM, Bigenwald C, Champiat S, Collins M, Carbonnel F, Postel-Vinay S, Berdelou A, Varga A, Bahleda R, Hollebecque A, Massard C, Fuerea A, Ribrag V, Gazzah A, Armand JP, Amellal N, Angevin E, Noel N, Boutros C, Mateus C, Robert C, Soria JC, Marabelle A, Lambotte O. Michot JM, et al. Eur J Cancer. 2016 Feb;54:139-148. doi: 10.1016/j.ejca.2015.11.016. Epub 2016 Jan 5. Eur J Cancer. 2016. PMID: 26765102 Review.
The first generation of new immunotherapies corresponds to antagonistic antibodies that block specific immune checkpoint molecules cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4), programmed cell death protein (PD-1) and its l …
The first generation of new immunotherapies corresponds to antagonistic antibodies that block specific immune checkpoint molecules cytoto
Immune Checkpoint Blockade in Cancer Therapy.
Postow MA, Callahan MK, Wolchok JD. Postow MA, et al. J Clin Oncol. 2015 Jun 10;33(17):1974-82. doi: 10.1200/JCO.2014.59.4358. Epub 2015 Jan 20. J Clin Oncol. 2015. PMID: 25605845 Free PMC article. Review.
Immunologic checkpoint blockade with antibodies that target cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) and the programmed cell death protein 1 pathway (PD-1/PD-L1) have demonstrated promise in a variety of malignancies. . …
Immunologic checkpoint blockade with antibodies that target cytotoxic T lymphocyte-associated antigen 4 ( …
Genetic basis for clinical response to CTLA-4 blockade in melanoma.
Snyder A, Makarov V, Merghoub T, Yuan J, Zaretsky JM, Desrichard A, Walsh LA, Postow MA, Wong P, Ho TS, Hollmann TJ, Bruggeman C, Kannan K, Li Y, Elipenahli C, Liu C, Harbison CT, Wang L, Ribas A, Wolchok JD, Chan TA. Snyder A, et al. N Engl J Med. 2014 Dec 4;371(23):2189-2199. doi: 10.1056/NEJMoa1406498. Epub 2014 Nov 19. N Engl J Med. 2014. PMID: 25409260 Free PMC article.
Ipilimumab and tremelimumab are antibodies against cytotoxic T-lymphocyte antigen 4 (CTLA-4). Anti-CTLA-4 treatment prolongs overall survival in patients with melanoma. CTLA-4 blockade activates T
Ipilimumab and tremelimumab are antibodies against cytotoxic T-lymphocyte antigen 4 (CTLA-4
Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination.
Boutros C, Tarhini A, Routier E, Lambotte O, Ladurie FL, Carbonnel F, Izzeddine H, Marabelle A, Champiat S, Berdelou A, Lanoy E, Texier M, Libenciuc C, Eggermont AM, Soria JC, Mateus C, Robert C. Boutros C, et al. Nat Rev Clin Oncol. 2016 Aug;13(8):473-86. doi: 10.1038/nrclinonc.2016.58. Epub 2016 May 4. Nat Rev Clin Oncol. 2016. PMID: 27141885 Review.
Inhibition of immune checkpoints using anti-programmed cell death-1 (PD-1) or anti cytotoxic-T-lymphocyte-associated antigen 4 (CTLA-4) monoclonal antibodies has revolutionized the management of patients with advanced-stage melanom …
Inhibition of immune checkpoints using anti-programmed cell death-1 (PD-1) or anti cytotoxic-T-lymphocyte-associated …
Immune checkpoints and their inhibition in cancer and infectious diseases.
Dyck L, Mills KHG. Dyck L, et al. Eur J Immunol. 2017 May;47(5):765-779. doi: 10.1002/eji.201646875. Epub 2017 Apr 24. Eur J Immunol. 2017. PMID: 28393361 Free article. Review.
The development of chronic infections and cancer is facilitated by a variety of immune subversion mechanisms, such as the production of anti-inflammatory cytokines, induction of regulatory T (Treg) cells, and expression of immune checkpoint molecules, including CTLA
The development of chronic infections and cancer is facilitated by a variety of immune subversion mechanisms, such as the production of anti …
Immune checkpoint blockade: a common denominator approach to cancer therapy.
Topalian SL, Drake CG, Pardoll DM. Topalian SL, et al. Cancer Cell. 2015 Apr 13;27(4):450-61. doi: 10.1016/j.ccell.2015.03.001. Epub 2015 Apr 6. Cancer Cell. 2015. PMID: 25858804 Free PMC article. Review.
Drugs interrupting immune checkpoints, such as anti-CTLA-4, anti-PD-1, anti-PD-L1, and others in early development, can unleash anti-tumor immunity and mediate durable cancer regressions. ...
Drugs interrupting immune checkpoints, such as anti-CTLA-4, anti-PD-1, anti-PD-L1, and others in early development, can unleas …
Combination cancer immunotherapy and new immunomodulatory targets.
Mahoney KM, Rennert PD, Freeman GJ. Mahoney KM, et al. Nat Rev Drug Discov. 2015 Aug;14(8):561-84. doi: 10.1038/nrd4591. Nat Rev Drug Discov. 2015. PMID: 26228759 Review.
Targeting immune checkpoints such as programmed cell death protein 1 (PD1), programmed cell death 1 ligand 1 (PDL1) and cytotoxic T lymphocyte antigen 4 (CTLA4) has achieved noteworthy benefit in multiple cancers by blocking immunoinhibitory sig …
Targeting immune checkpoints such as programmed cell death protein 1 (PD1), programmed cell death 1 ligand 1 (PDL1) and cytotoxic
What did we learn from CTLA-4 insufficiency on the human immune system?
Mitsuiki N, Schwab C, Grimbacher B. Mitsuiki N, et al. Immunol Rev. 2019 Jan;287(1):33-49. doi: 10.1111/imr.12721. Immunol Rev. 2019. PMID: 30565239 Review.
Cytotoxic-T-lymphocyte-antigen-4 (CTLA-4) is a negative immune regulator constitutively expressed on regulatory T (Treg) cells and upregulated on activated T cells. ...However, whether the pathology-causing activated
Cytotoxic-T-lymphocyte-antigen-4 (CTLA-4) is a negative immune regulator constitutively exp
10,190 results
Jump to page
Feedback